Is BPC-157 legal in the UK?

Last reviewed 9 August 2026

The short answer has three parts, and they belong to three different bodies of law. BPC-157 is not a controlled drug in the United Kingdom. No product containing it holds a marketing authorisation in any country. And nothing in UK law attaches legality to the molecule at all — what the Human Medicines Regulations 2012 regulate is the supply of a medicinal product, and whether a particular vial falls inside that definition turns partly on what its seller has said about it.

This page takes each regime in turn with the statutory reference or regulatory document behind it. It is the compound-level companion to Are research peptides legal in the UK?, which carries the general analysis. Every statement below is a statement about a rule or about a document; none is a statement about what the substance does.

Five questions, five regimes

Most pages answering this query collapse those five rows into one, and then err in one direction or the other: declaring the compound outright illegal, which no instrument says, or declaring it legal, which no instrument says either.

It is not a controlled drug

Paragraph 4 of Part II of Schedule 4 to the Misuse of Drugs Regulations 2001 lists, alongside the anabolic and androgenic steroids, a short and closed set of named substances: chorionic gonadotrophin (HCG), clenbuterol, non-human chorionic gonadotrophin, somatotropin, somatrem, somatropin, zeranol and zilpaterol. BPC-157 is not among them, and it appears nowhere else in the Schedules.

The consequence is concrete rather than academic. Unlawful supply of a Class C controlled drug carries a maximum of fourteen years on indictment under section 4 of the Misuse of Drugs Act 1971. Nothing in that Act reaches this sequence. The exposure sits entirely under medicines law, where the maximum is two years.

It holds no marketing authorisation, and that is documented rather than merely absent

This negative is normally asserted by inference from an empty register, which is weak. Two published documents state it positively instead.

The first is the FDA briefing document for the Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: There is no approved product containing BPC-157-related BDSs in any country at this time, nor is BPC-157 (free base) or BPC-157 acetate found in the European, Japanese, or the International Pharmacopeias. The same document records that there is no United States Pharmacopeia or National Formulary monograph for either form, and that neither is a component of an approved drug.

The second is the WADA Prohibited List. Class S0 covers any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and WADA has named BPC-157 in that class since 2022 — a standing assertion by an international body that no health regulator anywhere has approved it.

Where the Human Medicines Regulations actually bite

Regulation 2(1) of the Human Medicines Regulations 2012 defines a medicinal product on two alternative limbs — presentation and function — and MHRA Guidance Note 8 confirms that either alone is sufficient. The parent article sets both out in full; what follows is only how they apply to this sequence.

If either limb is engaged, regulation 46 prohibits selling, supplying or offering to sell or supply an unauthorised medicinal product; regulation 47 makes the breach an offence carrying, on indictment, a fine, imprisonment not exceeding two years, or both; and regulation 279 separately prohibits publishing an advertisement in Great Britain for a medicinal product with no authorisation in force. A claim therefore does two things at once: it brings the substance inside the definition, and the same words then constitute an advertisement for an unauthorised medicine.

The functional limb, and why the FDA file bears on it

The functional limb is the one a seller cannot write their way out of, because it is assessed on the substance. In Hecht-Pharma (C-140/07) the Court of Justice held that a product cannot be regarded as a medicinal product by function where, having regard to its composition and if used as intended, it is incapable of appreciably restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action. The burden lies on the authority to establish those properties, not on the supplier to disprove them.

That test needs evidence about the substance, and the fullest public assessment of this one is the July 2026 FDA review, whose findings run against the limb being satisfied on the current record. FDA reported that dose-response relationships have not been established, that the molecular targets have not been identified, that the mechanisms of action remain poorly understood, that the clinical safety information available was insufficient to characterise a safety profile, and that it found no study administering BPC-157 to humans by four of the five routes the nomination proposed.

That is a favourable position under limb two, for an uncomfortable reason: the evidence base is thin. It does not become thicker because it is legally convenient, and the protection lapses the moment pharmacological properties are established.

Buying, holding and importing are three different questions

Regulation 46 is directed at supply. Regulation 46(3) reaches possession, but only where the holder knows or has reasonable cause to believe the product is intended to be sold or supplied to another person within the United Kingdom or the European Economic Area — simple possession is not the target. Importation is governed separately by regulation 17, which requires a licence to import a medicinal product and carries its own narrow exemptions, including one for personal importation. Each is a distinct question with a distinct answer, and conflating them is where most published guidance on this topic goes wrong.

The anti-doping position is settled and is often reported incorrectly

The 2026 Prohibited List, in force from 1 January 2026, states at S0 that any pharmacological substance not addressed by a later section of the List, and with no current approval by any governmental regulatory health authority for human therapeutic use, is prohibited at all times. It then names the class members: This class covers many different substances including but not limited to BPC-157, 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers … and troponin activators. The class is prohibited in and out of competition, and the List records that All prohibited substances in this class are Specified Substances.

Two precisions follow.

BPC-157 is in S0 and not in S2.3. Section S2.3 covers growth factors and growth factor modulators, and names Thymosin-ß4 and its derivatives e.g. TB-500. The two classifications are mutually exclusive by construction, since S0 applies only to substances no later section addresses — so a page citing both for one compound has contradicted itself. The distinction also has a practical edge: S0 substances are Specified Substances while everything in S2 is non-Specified, and the two attract different treatment under the Code. In a blended presentation the two components therefore sit in different classes and must be stated separately, as they are in the entries for BPC-157, TB-500 and the blend.

It has been named continuously since 2022. The wording appears in the 2022, 2023, 2024, 2025 and 2026 Lists. That is worth stating because a 2025 peer-reviewed review in Pharmaceuticals records that the compound was temporarily banned by the World Anti-Doping Agency (WADA) in 2022 (it is not currently listed as banned by the WADA) — a parenthetical that matches neither the List in force when the review was published nor any List since. Regulatory status is checked against the instrument, not against the literature describing it.

In UK sport the point arrives through the UK Anti-Doping Rules, under which amendments made by WADA to the Prohibited List take effect automatically and bind everyone subject to those Rules.

What the analytical literature reports

Detection is a separate factual question from prohibition, and it has its own published record.

• Cox, Miller and Eichner (2017) investigated detection and in vitro metabolism of BPC 157, in material identified in confiscated vials and in plasma incubation, and reported a validated human-urine method with a limit of detection of 0.1 ng/mL and stability in urine for at least four days.
• Tian and colleagues (2023), at the Shanghai Anti-Doping Laboratory, investigated the metabolic profile of BPC-157 by stable-isotope labelling, in two in vitro incubation models, and reported nine metabolites and a validated human-urine method for the parent compound and five of them, at 0.01 to 0.11 ng/mL.
• Mazzarino and colleagues (2026) investigated a harmonised workflow for 54 prohibited compounds, in dried blood spots, serum and plasma, and reported detection limits of 0.05 to 1.25 ng/mL, with BPC-157 and TB-500 among those degrading completely in serum while remaining detectable in dried matrices.

The United States chronology, and what the July 2026 vote decided

Three things about that sequence are routinely misread.

The April 2026 change was not a finding of safety. The substances moved because the nominations were withdrawn, which is exactly how FDA’s published note describes them. FDA elected to present BPC-157 to the committee anyway.

The vote went against FDA’s own reviewers. The briefing document concludes: Accordingly, we propose not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List. A committee recommendation is advisory; the agency decides, by rulemaking that has not run.

The vote concerned one nominated use, not the compound at large. The nomination FDA evaluated was for ulcerative colitis, and three further proposed uses were not evaluated at all because the nomination did not contain enough information for the agency to assess them. Neither the review nor the vote is a finding that the substance does anything: FDA’s stated conclusion was that there is a lack of evidence to support the effectiveness for the nominated use.

None of this is UK law. It matters here because that file is the most complete public regulatory assessment of the substance in existence, and because the US intended-use rule at 21 CFR 201.128 runs on the same logic the Court of Justice applied in Delattre (C-369/88), where a statement that a product is not medicinal was held to be persuasive evidence which the national court may take into consideration but is not in itself conclusive.

What the enforcement record shows

The FDA letter of 12 June 2023 names BPC-157 directly and states the reasoning plainly: Despite statements on [the] product labeling marketing [the] products for ‘research purpose only’ and ‘not for human consumption,’ evidence obtained from [the] website establishes that [the] products are intended to be drugs for human use. The letter then reproduces the seller’s own website copy, which named specific disease conditions and asserted therapeutic potential. It was that copy, not the identity of the molecule, that carried the finding.

A letter of 31 March 2026 to a different firm extends the point. FDA treated the bacteriostatic water that firm sold alongside its peptide products as itself a drug, reasoning that offering the two together evidenced the intended use of the diluent. Adjacency was the whole of the argument. MHRA Guidance Note 8 arrives at the same place by a different road, listing juxtaposing with any examples of the above among the forms of marketing that may indicate a product is properly classified as a medicine.

In the United Kingdom, MHRA’s Criminal Enforcement Unit is active in this market: two arrests followed a seizure of unlicensed medicines near Northampton on 28 May 2026, on suspicion of offences under the Human Medicines Regulations 2012 rather than under any bespoke peptide legislation, because none exists. That action named retatrutide and tirzepatide together with peptide products. It did not name BPC-157, and this page does not suggest otherwise.

The identity problem underneath the legal one

Every question above presupposes that the substance in the vial is the substance being discussed, and FDA’s review states that this cannot be assumed:

“BPC-157 is a common name and not a United States Adopted Name (USAN). FDA has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name.”

On that basis, and on gaps in the characterisation data, FDA concluded that both forms are not well-characterized from the physical and chemical characterization perspective. A name on a label is not an identification. The checkable identifiers are the CAS number, the molecular formula, the sequence and the expected mass, which is why they are published in full in the library entry for this compound.

What this page does not settle

The functional-limb question is open, not answered. Hecht-Pharma shields a substance whose pharmacological properties are not established, and that shield is contingent on the state of the science. Mendias and Awan (2026) published a narrative review of approved and unapproved peptides used in musculoskeletal and athletic contexts, and reported that rigorous human safety data for the unapproved compounds are scarce.

Classification determinations are product-specific and are not precedent. MHRA classifies finished products case by case, and says so in Guidance Note 8.

This is analysis, not legal advice. It is a reading of published instruments and regulatory documents, current at the date shown, and cannot substitute for advice on a specific product. Anyone needing certainty can request a formal opinion through MHRA’s borderline advice route.

Sources

• Human Medicines Regulations 2012, regulation 2 (definition); regulation 17 (manufacture and importation); regulation 46; regulation 47; regulation 279 (advertising).
• Misuse of Drugs Regulations 2001, Schedule 4, Part II, paragraph 4; Misuse of Drugs Act 1971, sections 4 and 5.
• MHRA Guidance Note 8, A guide to what is a medicinal product, published September 2025 — sections 4, 5, 6 and 7.
• Case C-140/07 Hecht-Pharma (judgment 15 January 2009); Case C-369/88 Delattre (judgment 21 March 1991) — both as reported in Guidance Note 8, Appendix 3.
• WADA 2026 Prohibited List, in force 1 January 2026, class S0 and section S2.3; and the 2022, 2023, 2024 and 2025 Lists.
• UK Anti-Doping Rules 2021, article 1.7 (automatic incorporation of amendments to the Prohibited List).
• FDA, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026, and the FDA briefing document for BPC-157-related bulk drug substances.
• FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (category 2 table and the nominated-but-withdrawn list).
• FDA warning letters: MARCS-CMS 655280, 12 June 2023; MARCS-CMS 721806, 31 March 2026. 21 CFR 201.128.
• MHRA news, “Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines”, 29 May 2026.
• Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490–1498. PMID 28035768. DOI 10.1002/dta.2152.
• Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y. Stable isotope labeling-based nontargeted strategy for characterization of the in vitro metabolic profile of a novel doping BPC-157 in doping control by UHPLC-HRMS. Molecules. 2023;28(21):7345. PMID 37959764. DOI 10.3390/molecules28217345.
• Mazzarino M, Colpaert T, Deventer K, Van Eenoo P. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. Analyst. 2026;151(15):4398–4413. PMID 42328738. DOI 10.1039/d6an00455e.
• Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide — literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. PMID 40005999. DOI 10.3390/ph18020185.
• Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026 Apr 12 [Epub ahead of print]. PMID 41966639. DOI 10.1007/s40279-026-02437-0.